On Tuesday, Loop Capital, a financial services firm, raised the price target for Tempus AI Inc (NASDAQ:TEM) shares to $57, up from the previous $48. The firm has continued to endorse the stock with a Buy rating. This adjustment reflects new estimates that include the financial effects of the company's joint venture with Softbank (OTC:SFTBY).
The updated valuation by Loop Capital takes into account an expected quarterly $10 million loss on investments related to Softbank, which will impact the GAAP earnings per share (EPS). However, the total revenue and non-GAAP EPS projections for Tempus AI remain unaltered despite this charge.
Tempus AI, known for its cutting-edge healthcare data platform, is recognized for its role in the emerging field of precision medicine and genomics, which is expected to become a standard in healthcare. The company's extensive network includes physicians, hospitals, and pharmaceutical and biotech firms that use and license its oncology data.
The company's growth trajectory is characterized by a low-30% increase, and although currently experiencing investment-driven losses, Loop Capital anticipates that Tempus AI's operating margins will improve, turning to modest profits by the end of 2025. The stock is currently trading at approximately 6.5 times its estimated 2026 enterprise value to revenue. Loop Capital's endorsement reflects confidence in the company's growth potential and market position.
In other recent news, Tempus AI has been making strategic moves in the tech industry. The company's CEO, Eric Lefkofsky, has decided to defer the settlement of about 4.47 million restricted stock units (RSUs), pushing the settlement period to between January 15, 2025, and March 15, 2025. During this Deferred Settlement Period, Tempus AI is expected to undertake mandatory sell-to-cover transactions to fulfill tax withholding and remittance obligations related to the RSU settlements.
Tempus AI has also increased its stake in Personalis (NASDAQ:PSNL), Inc. through a $36 million investment, acquiring shares and exercising warrants for additional stock. In line with this, Tempus AI and Personalis have amended their existing Commercialization Agreement, extending the notice period for termination for convenience to 30 months and enhancing commitments related to maintaining laboratory capacity for new patients under certain conditions.
Several financial firms have been keeping a close eye on Tempus AI. Piper Sandler initiated coverage with a Neutral rating, emphasizing the need for Tempus AI to increase its revenue in the AI segment for future rating adjustments. On the other hand, both BofA Securities and Loop Capital initiated coverage with a Buy rating, recognizing Tempus AI's integration of artificial intelligence with healthcare and diagnostics, and its substantial market opportunity.
In the realm of technological advancements, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. This marks a significant advancement in the field of cardiovascular machine learning-based notification software.
InvestingPro Insights
Building on Loop Capital's optimistic outlook for Tempus AI Inc (NASDAQ:TEM), recent data from InvestingPro provides additional context to the company's financial position and market performance. Despite the anticipated losses mentioned in the article, InvestingPro data shows that Tempus AI has experienced strong recent momentum, with a 38.58% price return over the last three months and a 26.01% return over the past six months.
InvestingPro Tips highlight that while Tempus AI operates with a moderate level of debt and has liquid assets exceeding short-term obligations, it is not currently profitable. This aligns with Loop Capital's projection of modest profits potentially emerging by late 2025. The company's Price to Book ratio of 79.66 indicates that investors are placing a high premium on its future potential, likely due to its position in the promising precision medicine and genomics fields.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide deeper insights into Tempus AI's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.